• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >CD44 as a drug delivery target in human cancers: where are we now?
【24h】

CD44 as a drug delivery target in human cancers: where are we now?

机译：CD44作为人类癌症的药物递送靶标：我们现在在哪里？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the treatment of cancers, the dual goals of drug targeting are to deliver therapeutic agents more selectively to tumor tissue and to minimize exposure of normal tissues and organs to those agents, the latter causing toxicities that limit treatment and thereby attenuate clinical efficacy. CD44, a transmembrane proteoglycan, has been considered as a targetable candidate to generate a cancer-specific drug delivery axis. Although numerous preclinical studies showed promising results exploiting CD44 as such a target, results of two clinical trials, including a Phase III registration trial, have been very disappointing. Herein, we discuss the potential underlying causes that might have led to such failures, as well as the future of CD44-targeted cancer treatment.
机译：在癌症的治疗中，靶向药物的双重目标是将治疗剂更选择性地递送至肿瘤组织，并使正常组织和器官与那些治疗剂的接触减至最小，后者导致毒性，从而限制了治疗，从而削弱了临床疗效。 CD44，一种跨膜蛋白聚糖，被认为是产生癌症特异性药物递送轴的可靶向候选物。尽管大量的临床前研究表明，将CD44用作此类靶标的结果令人鼓舞，但两项临床试验（包括III期注册试验）的结果却令人非常失望。在本文中，我们讨论了可能导致此类失败的潜在潜在原因，以及针对CD44的癌症治疗的未来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号